Astria Therapeutics, Inc.
NASDAQ:ATXS
9.15 (USD) • At close December 27, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0.026 | 0.119 | 0 | 0.395 | 0.202 | 0 | 0 | 0 |
| Gross Profit
| 0 | 0 | 0 | 0 | -0.026 | -0.119 | 0.5 | -0.395 | -0.202 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 57.326 | 34.264 | 15.552 | 25.59 | 18.317 | 17.042 | 18.682 | 25.45 | 23.03 | 15.686 | 13.994 | 0.012 |
| General & Administrative Expenses
| 25.704 | 19.239 | 14.807 | 11.845 | 8.771 | 9.329 | 8.912 | 10.108 | 8.629 | 5.995 | 4.125 | 0.003 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001 |
| SG&A
| 25.704 | 19.239 | 14.807 | 11.845 | 8.771 | 9.329 | 8.912 | 10.108 | 8.629 | 5.995 | 4.125 | 0.004 |
| Other Expenses
| 0 | -0.055 | -0.058 | -0.101 | -0.05 | 0.176 | 0.032 | 0.093 | 0.007 | 0.003 | 0.001 | 0 |
| Operating Expenses
| 83.03 | 53.503 | 30.359 | 37.435 | 27.088 | 26.371 | 27.594 | 35.558 | 31.659 | 21.681 | 18.119 | 0.016 |
| Operating Income
| -83.03 | -53.503 | -194.976 | -37.435 | -27.088 | -26.371 | -27.094 | -35.558 | -31.659 | -21.681 | -18.119 | -0.016 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -54.188 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 10.139 | 1.669 | 0.064 | 0.135 | 0.795 | 0.501 | -0.27 | -0.502 | -0.971 | -0.203 | 0.001 | 0 |
| Income Before Tax
| -72.891 | -51.834 | -194.912 | -37.3 | -26.293 | -25.87 | -27.364 | -36.06 | -32.63 | -21.884 | -18.118 | -0.016 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -54.728 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -1.669 | -164.739 | -0.236 | -0.05 | 0.601 | 0.494 | 0.93 | 0.783 | 0.209 | 0 | 0 |
| Net Income
| -72.891 | -50.165 | -30.173 | -37.064 | -26.243 | -25.87 | -27.364 | -36.06 | -32.63 | -21.884 | -18.118 | -0.016 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -54.728 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.108 |
| EPS Diluted
| -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.108 |
| EBITDA
| -83.03 | -53.503 | -194.976 | -37.435 | -26.267 | -25.651 | -26.598 | -34.828 | -31.459 | -21.43 | -17.799 | -15.342 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -53.196 | 0 | 0 | 0 | 0 | 0 |